mRNA |
GSK525762A |
CTRPv2 |
pan-cancer |
AAC |
0.023 |
0.4 |
mRNA |
BRD-K58730230 |
CTRPv2 |
pan-cancer |
AAC |
-0.055 |
0.4 |
mRNA |
MLN2238 |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.4 |
mRNA |
N9-isopropylolomoucine |
CTRPv2 |
pan-cancer |
AAC |
0.027 |
0.4 |
mRNA |
SJ-172550 |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.039 |
0.5 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.5 |
mRNA |
BRD-K27224038 |
CTRPv2 |
pan-cancer |
AAC |
0.054 |
0.5 |
mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.5 |
mRNA |
BRD-K66453893 |
CTRPv2 |
pan-cancer |
AAC |
0.023 |
0.5 |